Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625
This examiner grants 69% of resolved cases
Sara Elizabeth Bell is an examiner in Tech Center 1600, working within Art Unit 1621. The examiner has handled 64 resolved cases, which provides an informative dataset. The allowance rate is 68.8 percent, showing the frequency of granted patents on this docket. This 68.8 percent figure serves as the primary benchmark for applicants evaluating their chances of success. The 64 resolved cases establish the current record for this examiner.
The interview lift is 38.2 percent, which is a significant metric in this profile. This 38.2 percent lift indicates that conducting an interview correlates with a higher probability of allowance compared to cases without one. When viewed alongside the 68.8 percent allowance rate, the data suggests that oral advocacy is a driver of successful prosecution. The median days to allowance is 1356, which is the typical timeframe for applications that reach a grant. This 1356 median days to allowance reflects the pace of prosecution.
The data in Art Unit 1621 shows that the interview lift is 38.2 percent, providing a clear strategy for applicants. The 1356 median days to allowance helps set expectations for the overall timeline in Tech Center 1600. Given the 68.8 percent allowance rate, applicants have a documented chance of success. These statistics provide a basis for strategic planning during the examination process and help in managing client expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18323240 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | Final Rejection | Genentech, Inc. |
| 17428080 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18286185 | TREATMENT METHODS AND COMPOSITIONS COMPRISING PERAMPANEL | Final Rejection | The Johns Hopkins University |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17642285 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Non-Final OA | NOVARTIS AG |
| 18532424 | Papain-like protease (PLpro) inhibitors | Non-Final OA | Pfizer Inc. |
| 18027785 | TRIAZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE | Final Rejection | TOSOH CORPORATION |
| 18192313 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | Non-Final OA | INCYTE CORPORATION |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Non-Final OA | CELGENE CORPORATION |
| 17598665 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | Final Rejection | Cardiff Oncology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy